UDK: 615.065:615.273.53-616.14-002

APPLICATION OF A HAS-BLED SCORING SYSTEM TO ASSESS THE RISK OF HEMORRHAGIC COMPLICATIONS OF ANTICOAGULANT THERAPY IN PATIENTS WITH DEEP VEIN THROMBOSIS OF THE LOWER EXTREMITIES

O. V. Shatalova, A. S. Maslakov

Волгоградский государственный медицинский университет, кафедра клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ

Abstract

A prospective study of high bleeding risk patients (HAS-BLED 3 points) showed that patients who received warfarin were more likely to develop major and clinically relevant non-major bleeding events. The study of low bleeding risk patients (HAS-BLED < 2 points) showed that patients who received warfarin were more likely to develop clinically relevant non-major bleeding events.

Keywords

HAS-BLED, rivaroxaban, warfarin, deep vein thrombosis, hemorrhagic complications.

Contacts

Маслаков Александр Сергеевич — аспирант кафедры клинической фармакологии и интенсивной терапии, Волгоградский государственный медицинский университет, e-mail: doctor.al.87@gmail.com